✦ LIBER ✦

Future prospects in immunosuppression for liver transplantation

✍ Scribed by John J. Fung; Jessica E. Bollinger; Charles Miller; Bijan Eghtesad

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 100 KB
Volume: 17
Category: Article
ISSN: 1527-6465
DOI: 10.1002/lt.22412

No coin nor oath required. For personal study only.

✦ Synopsis

Key Points

Our increasing understanding of signaling pathways and cellular interactions in transplant immunobiology and the availability of novel immunosuppressive agents have facilitated targeted strategies. 2. The driving forces behind the development of new immunosuppressive regimens are the long-term complications of current immunosuppressive regimens (particularly renal dysfunction and metabolic disturbances). 3. By regulatory mandate, the requirement for the primary endpoint to be a composite of death, graft loss, and rejection remains intact; however, current and future clinical trials could incorporate key secondary endpoints that address renal and metabolic derangements.

📜 SIMILAR VOLUMES

Immunosuppression in liver transplantati

Immunosuppression in liver transplantation

✍ David J. Post; David D. Douglas; David C. Mulligan 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB

E arly mythology depicts two saints in a life-and- death struggle to save a limb from a foregone fate. Saints Cosmos and Damien replaced a cancerous leg with a limb from a deceased Moor. This illustration was mere fantasy until the latter part of the previous century with the seminal surgeries perfo

Future prospects in transplantation

✍ Dr Anne Baron-Van Evercooren 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 769 KB

Immunosuppression in liver transplantati

Immunosuppression in liver transplantation: Beyond calcineurin inhibitors

✍ John Fung; Dympna Kelly; Zakiyah Kadry; Kusum Patel-Tom; Bijan Eghtesad 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB

Although calcineurin inhibitors (CNIs) remain the mainstay of immunosuppression in liver transplantation (LTX), their long-term toxicity significantly contributes to morbidity and mortality. The elucidation of mechanisms of alloimmunity and leukocyte migration have provided novel targets for immunos

Sirolimus-based immunosuppression follow

Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma

✍ Michael A. Zimmerman; James F. Trotter; Michael Wachs; Tom Bak; Jeffrey Campsen; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB

Experience with sirolimus (SRL)-based immunosuppression following orthotopic liver transplantation (OLT) is rapidly accumulating. In combination with calcineurin inhibitors (CNIs), SRL may reduce the incidence of acute rejection and lower overall required drug levels. This study sought to quantify l

Liver transplantation from non–heart-bea

Liver transplantation from non–heart-beating donors: Current status and future prospects

✍ Srikanth Reddy; Miguel Zilvetti; Jens Brockmann; Andrew McLaren; Peter Friend 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

Liver transplantation is the treatment of choice for many patients with acute and chronic liver failure, but its application is limited by a shortage of donor organs. Donor organ shortage is the principal cause of increasing waiting lists, and a number of patients die while awaiting transplantation.

Immunosuppression for liver transplantat

Immunosuppression for liver transplantation in HCV-infected patients: Mechanism-based principles

✍ Bijan Eghtesad; John J. Fung; Anthony J. Demetris; Noriko Murase; Roberta Ness; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB

We retrospectively analyzed 42 hepatitis C virus (HCV)infected patients who underwent cadaveric liver transplantation under two strategies of immunosuppression: (1) daily tacrolimus (TAC) throughout and an initial cycle of high-dose prednisone (PRED) with subsequent gradual steroid weaning, or (2)